What was the primary driver for the significant revenue and profit increase in this quarter?

The primary driver was the substantial increase in sales of COVID-19 diagnostic testing solutions, particularly within the Life Sciences segment, which generated approximately $867 million in revenue. This was complemented by growth in other segments due to increased healthcare utilization and demand for specific medical products related to the pandemic.

What are the main risks or challenges the company is facing?

The company faces ongoing risks related to product liability claims, particularly for hernia repair devices, pelvic mesh devices, and vena cava filters, which have led to significant litigation accruals. Additionally, regulatory scrutiny, such as the FDA's actions regarding the BD AlarisTM infusion pumps, and broader uncertainties from the COVID-19 pandemic on supply chains and demand for elective procedures, are notable challenges.

How is the company managing its debt and liquidity?

The company generated strong operating cash flow of $1.533 billion and maintained a healthy cash balance of $3.464 billion as of December 31, 2020. While total debt remains substantial, short-term debt as a percentage of total debt increased, reflecting a reclassification. The company has a revolving credit facility in place and is in compliance with its covenants, indicating a stable liquidity position.

What is the outlook for the company given the current economic climate and pandemic?

The company's outlook is heavily influenced by the ongoing COVID-19 pandemic. While diagnostic testing and certain medical products have seen a surge, demand for procedure-based products could remain volatile. Management is focused on navigating supply chain challenges, investing in growth initiatives, and managing regulatory and legal matters. The company remains committed to innovation and operational efficiency to sustain long-term growth.

BDX 10-Q Quarterly Report Q1 FY2021 — Revenue, Net Income, EPS

Summary

Becton, Dickinson and Company (BDX) reported a significant increase in revenue and net income for the three months ended December 31, 2020, compared to the same period in the prior year. This surge was primarily driven by strong demand for COVID-19 diagnostic testing solutions, particularly within the Life Sciences segment. The company also saw revenue growth across its Medical and Interventional segments, benefiting from increased healthcare utilization and specific product demands related to the pandemic. Despite the overall positive financial performance, investors should note the ongoing impact of the COVID-19 pandemic on global supply chains and demand for non-essential procedures. The company continues to manage significant legal and regulatory challenges, particularly concerning product liability claims and ongoing investigations, which could materially affect future results. However, BDX demonstrated robust cash flow generation and maintained a solid liquidity position.

Financial Highlights

52 data points

Beta

Revenue

$5.32B

0.5% Gross Margin

Net Income

$1.00B

0.2% Net Margin

EPS (Diluted)

$3.35

Total Assets

$54.75B

Cash & Equivalents

$3.25B

Free Cash Flow

$1.29B

Financial Statements

Beta

Revenue	$5.32B
Cost of Revenue	$2.58B
Gross Profit	$2.73B
R&D Expenses	$291.00M
SG&A Expenses	$1.15B
Operating Expenses	$4.07B
Operating Income	$1.24B
Interest Expense	$118.00M
Net Income	$1.00B
EPS (Basic)	$3.38
EPS (Diluted)	$3.35
Shares Outstanding (Basic)	290.59M
Shares Outstanding (Diluted)	293.11M

Key Highlights

1Total revenues increased by 25.8% to $5.315 billion for the three months ended December 31, 2020, compared to $4.225 billion in the prior year period.
2Net income surged to $1.003 billion, a substantial increase from $278 million in the prior year period, with diluted EPS rising to $3.35 from $0.87.
3The Life Sciences segment experienced exceptional growth (76.2%) driven by COVID-19 diagnostic testing, contributing $867 million in sales.
4Despite a hold on certain U.S. shipments of BD AlarisTM infusion pumps, the Medical segment saw 8.2% revenue growth, with strong performance in Medication Delivery Solutions and Pharmaceutical Systems.
5Operating cash flow was robust at $1.533 billion for the quarter, demonstrating strong operational performance.
6The company maintained a healthy cash position with $3.464 billion in cash and short-term investments as of December 31, 2020.
7Significant legal matters, including numerous product liability claims, continue to be a focus, with accruals for product liability claims totaling approximately $2.4 billion.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions